SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study
{{output}}
Elevated lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular disease and may accelerate chronic kidney disease (CKD) progression. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated renal protective effects, but their role in patie... ...
